Abstracts tagged "lupus nephritis and biomarkers"

Abstract Number: 696 • 2019 ACR/ARP Annual Meeting
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
Najla Aljaberi¹, Qing Ma ², Theresa Hennard ³, Arjun Mathur ⁴ and Hermine Brunner ⁵, ¹Divison of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus nephritis (LN) is associated with high morbidity and mortality. Current standard tools to monitor LN are suboptimal compared to the invasive renal biopsy.…
Abstract Number: 1583 • 2019 ACR/ARP Annual Meeting
Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus
Jose A Gómez-Puerta¹, Tomás Urrego ², Blanca Ortiz Reyes ³, Adriana Vanegas-García ⁴, Carlos H Muñoz-Vahos ⁴, Luis A González ⁴ and Gloria Vasquez ⁵, ¹Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Antioquia, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵University of Antioquia, Medellin, Antioquia, Colombia
Background/Purpose: Background: There is an increasing knowledge about the utility of urinary biomarkers for the diagnosis of lupus nephritis (LN) in patients with systemic lupus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].